Floatz logo

Mirtazapine

Nutritional Deficiency Disease

Montefiore Medical CenterSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Nutritional Deficiency Disease cohort.

Asset / SponsorPhaseRating
Intralipid
Johane Allard
Phase 4BB
Retrovir
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Methoxy Polyethylene Glycol-Epoetin Beta
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Lamivudine
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BB

View all 31 →

Same molecule, other indications

Mirtazapine is also rated in:

major depressive disorderActive
BB
Indicative · Phase 4
70 / 100
View asset →
depressive disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cancer-related conditionDormant
BB
Indicative · Phase 4
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →